Isotechnika Inc. To Host Analyst And Investor Meeting In New York City

EDMONTON, Nov. 8 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that the company will hold an Analyst and Investor Meeting on Thursday, November 10, 2005 from 7:30 a.m. to 11:00 a.m. at the Four Seasons Hotel in New York City on 57 E. 57th Street.

Isotechnika will discuss its lead immunosuppressive drug, ISA247’s current and future clinical programs with presentations from management, clinical investigators and key opinion leaders.

“This event is an opportunity for analysts and investors to get an in depth view of our company, the management team, and our pipeline,” stated Dr. Robert Foster, Isotechnika’s Executive Chairman. “We believe it is important to provide in depth scientific details and insight into the Company to help the investment community understand our product pipeline and its value.”

This event can be accessed by going to Isotechnika’s corporate Web site at www.isotechnika.com and clicking on the web cast link provided on the home page. The event will be archived and available for replay approximately two hours following the event.

About Isotechnika -----------------

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika’s lead compound, ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis. In addition, ISA247 has successfully completed a Phase IIa trial for kidney transplantation. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which is in Phase I.

In addition to the Company’s drug pipeline, Isotechnika also has a diagnostic division, which includes the Helikit(R) and Diatest(R) breath kits. The Helikit(R) a (13)C urea breath test is used for the detection of H. pylori, a bacterium that infects a large portion of the population. The Diatest(R) a (13)C glucose breath test is used to measure insulin resistance.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.

Partnerships ------------

Isotechnika Inc. has a collaboration agreement with Hoffman La Roche which licensed the worldwide rights to develop and commercialize Isotechnika’s novel molecule ISA247 for all transplant indications.

In addition, the Company has an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company’s belief as to the potential of its products, the Company’s expectations regarding the issuance of additional patents and the Company’s ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company’s patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company’s quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

Isotechnika Inc.

CONTACT: Dr. Robert Foster, Executive Chairman, Isotechnika Inc., (780)487-1600 (246), (780) 484-4105 (fax), rfoster@isotechnika.com; StephanieGillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc.,(780) 487-1600 (243), (780) 484-4105 (fax),sgillis-paulgaard@isotechnika.com; Archived images on this organization aresearchable through CNW Photo Archive website at http://photos.newswire.ca.Images are free to accredited members of the media. To request a free copyof this organization’s annual report, please go to http://www.newswire.caand click on Tools for Investors.

MORE ON THIS TOPIC